The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection (Q26864494)

language of work or name

1 reference

2013

1 reference

Clinical and Developmental Immunology

11 June 2013

11 references

13 March 2019

23 March 2019

22 March 2019

22 June 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

1 July 2020

27 October 2020

6 February 2021

12 references

13 March 2019

23 March 2019

22 March 2019

22 June 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

1 July 2020

27 October 2020

6 February 2021

2013

1 reference

page(s)

359683

1 reference

Creative Commons Attribution 3.0 Unported

copyright license

11 references

13 March 2019

23 March 2019

22 March 2019

22 June 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

1 July 2020

27 October 2020

on focus list of Wikimedia project

6 February 2021

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Mortality associated with influenza and respiratory syncytial virus in the United States

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Immunology of bovine respiratory syncytial virus infection of cattle

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Antibodies for prevention and treatment of respiratory syncytial virus infections in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Down syndrome and hospitalizations due to respiratory syncytial virus: a population-based study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Palivizumab prophylaxis in 'late preterm' newborns

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Cost effectiveness of palivizumab in Spain: an analysis using observational data.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

The burden of respiratory syncytial virus infection in young children

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Chronic lung disease after premature birth.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

28 September 2017

Bronchiolitis in infants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Respiratory syncytial virus infection

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Correlation between respiratory syncytial virus genotype and severity of illness

31 May 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33 weeks GA or more: preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Can respiratory syncytial virus etiology be diagnosed clinically? A hospital-based case-control study in children under two years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

High risk of nosocomial-acquired RSV infection in children with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Respiratory virus infections in pediatric hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Immunoprophylaxis and immunotherapy: role in the prevention and treatment of repiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Palivizumab use in very premature infants in the neonatal intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Safety and immunogenicity of palivizumab (Synagis) administered for two seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Respiratory syncytial virus risk factors in late preterm infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2013%2F359683

Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Immunoprophylaxis of respiratory syncytial virus infection.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3693113

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/23840240

12 December 2020

inferred from PubMed ID database lookup

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23840240

12 December 2020

inferred from PubMed ID database lookup

Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/23840240

12 December 2020

inferred from PubMed ID database lookup

Identifiers

1 reference

release_6yaah33oknhotpa3jzixxstbsy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6yaah33oknhotpa3jzixxstbsy

24 November 2022

mapped directly with Wikidata item

1 reference

PubMed publication ID

23840240

1 reference